Wegovy semaglutide tablets and Rybelsus are both oral semaglutide. Both are made by Novo Nordisk, and both use the same technology to help the medicine survive your digestive system. At first glance, they look remarkably similar.
But they're different medicines. They're licensed for different conditions and were approved years apart. Their dose ranges overlap at 1.5mg, 4mg and 9mg, but Wegovy tablets also go up to 25mg.1,2 Here's what actually sets them apart.
Same active ingredient, different jobs. Rybelsus is for type 2 diabetes, Wegovy tablets are for weight management.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone called GLP-1 (glucagon-like peptide-1), which your body naturally releases after you eat.
GLP-1 tells your brain you've eaten, slows how quickly food leaves your stomach and triggers insulin release when your blood sugar rises. By activating the same receptors, semaglutide reduces appetite, helps control blood sugar and supports weight loss.
GLP-1 medicines don't burn fat. They make it easier to eat less, and that's where the weight loss comes from.
Novo Nordisk makes semaglutide in several forms. The injections are Ozempic (licensed for type 2 diabetes) and Wegovy (licensed for weight management). The tablets are Rybelsus (licensed for type 2 diabetes) and Wegovy tablets (licensed for weight management).
All four contain the same active molecule. What differs is the dose, the licensed use and, for the tablets, the formulation that makes absorbing it by mouth possible.
What is Rybelsus?
Rybelsus is an oral semaglutide tablet licensed in the UK by the MHRA for adults with type 2 diabetes whose blood sugar isn't well controlled by diet and exercise alone.1 It isn't licensed for weight management.
It comes in three strengths, starting low and increasing gradually. The current UK formulation, introduced in 2025 with improved absorption, starts at 1.5mg once a day for a month.1,3 It then goes up to 4mg. After at least another month, it can go up to 9mg once a day if more blood sugar control is needed. That's the maximum.1
You should only ever take one Rybelsus tablet a day. Do not take more than one tablet to get a higher dose.1,3
Rybelsus tablet strengths changed in 2025. If you have been switched, check your new dose with your pharmacist.
These doses are designed for blood sugar management, not the higher level of GLP-1 activity needed for significant weight loss.
Rybelsus has to be taken on an empty stomach, after a fast of at least 8 hours. Swallow it whole with a sip of water, up to 120ml. Then wait at least 30 minutes before eating, drinking or taking other oral medicines.1
Wegovy tablets have the same rule.2 Waiting less than 30 minutes lowers how much semaglutide you absorb.1
What are Wegovy tablets?
Wegovy tablets are taken in steps of 1.5mg, 4mg, 9mg and 25mg. The 25mg maintenance dose is much higher than the maximum Rybelsus dose.1,2 They're licensed specifically for weight management in adults with obesity (a BMI of 30 or above), or overweight (a BMI of 27 or above) with at least one weight-related health condition.2
Wegovy tablets follow the same routine as Rybelsus: an 8-hour fast, a small sip of water, then a 30-minute wait.
The MHRA approved Wegovy tablets on 11 June 2026. They're the UK's first GLP-1 tablet for weight loss.4
The dose titration for Wegovy tablets starts at 1.5mg once a day. After a month it goes up to 4mg, then 9mg, then the maintenance dose of 25mg once a day, with at least a month at each step. If needed, you can stay on the previous dose for longer.2 This gradual step-up gives your digestive system time to adjust.
How are the two tablets different?
They share an active ingredient, but Wegovy tablets and Rybelsus differ in several important ways.
Licensed indication
This is the most important difference. Rybelsus is licensed for type 2 diabetes only. Wegovy tablets are licensed for weight management in people who meet the BMI criteria, whether or not they have diabetes.
Using Rybelsus for weight loss without a type 2 diabetes diagnosis would be off-label, outside what its MHRA approval covers.1
Dose range
Rybelsus goes up to a maximum of 9mg a day in the current UK formulation. Wegovy tablets go up to 25mg a day.1,2
The two ranges overlap at 1.5mg, 4mg and 9mg, so the same number on the box doesn't mean the same medicine or the same use.
Do not swap Rybelsus and Wegovy tablets, or take them together, unless a prescriber tells you to. They are not interchangeable.
Regulatory history and UK availability
Rybelsus is licensed in the UK for type 2 diabetes only. Its tablets were reformulated in 2025, which changed the strengths.1,3 Wegovy tablets received MHRA approval on 11 June 2026 for weight management.4
How absorption works
Both tablets use an ingredient called SNAC (salcaprozate sodium) to help semaglutide survive your stomach. When the tablet dissolves, SNAC creates a small zone of higher pH next to your stomach lining.
This reduces the activity of a digestive enzyme called pepsin, and helps semaglutide pass through the stomach wall into your bloodstream.5 Without SNAC, digestive enzymes would break semaglutide down before it could be absorbed.
The reformulated Rybelsus absorbs better, which is why the same effect is now reached at lower doses.3 Even so, only around 1 to 2% of an oral semaglutide dose reaches your bloodstream, and food or large amounts of water lower that further.2 That's why both tablets have the same fasting rule.
Because the brand and the milligram strength can't tell you what an equivalent dose is, never swap between the two yourself.
Why are the doses so different?
The gap between Rybelsus (up to 9mg) and Wegovy tablets (25mg) comes down to how each medicine is licensed and how it's absorbed.
“Rybelsus goes up to 9mg a day, while Wegovy tablets go up to 25mg a day. Do not take more than one Rybelsus tablet a day to try to copy a higher dose, as that can mean an overdose. The MHRA flagged this medication error risk when Rybelsus was reformulated in 2025.
Ana Carolina GoncalvesSuperintendent Pharmacist
For blood sugar control in type 2 diabetes, GLP-1's main job is to prompt insulin release after meals, with some appetite reduction on the side. In the PIONEER trials, which used the original Rybelsus formulation at doses up to 14mg, Rybelsus lowered HbA1c, a long-term measure of blood sugar, in people with type 2 diabetes.6
For weight management, Wegovy tablets use a higher dose. The Wegovy injection is 2.4mg a week and goes straight under your skin, bypassing your digestive system. Oral semaglutide is absorbed far less efficiently, so the tablet needs a much bigger dose.
In people with overweight or obesity, 25mg tablets gave average blood levels of semaglutide similar to the 2.4mg weekly injection, with more variation from person to person.2
Do not take several Rybelsus tablets to try to copy a Wegovy tablet dose. Rybelsus is licensed as one tablet a day, and taking more is an overdose that can increase side effects.1,3 The MHRA flagged this specific medication error risk during the 2025 Rybelsus reformulation.3
What does the clinical evidence show?
The evidence for each product reflects what it's designed to do.
Rybelsus in type 2 diabetes
The PIONEER trials looked at oral semaglutide in people with type 2 diabetes. In PIONEER 1, the highest dose tested (14mg of the original formulation) lowered HbA1c by around 1.1 percentage points more than placebo over 26 weeks.6
Weight loss was a secondary measure. People on the highest dose lost around 2.3kg more than those on placebo over the same period.6
The two trial programmes measured different things: blood sugar for Rybelsus, body weight for Wegovy tablets.
Wegovy tablets in weight management
The phase 3 OASIS 4 trial tested oral semaglutide 25mg in 307 adults with obesity or overweight who didn't have diabetes, over 64 weeks.
People taking the 25mg tablet alongside lifestyle support lost an average of 13.6% of their body weight, compared with 2.2% on placebo.7 A separate estimate, of what would happen if everyone had stayed on treatment, was 16.6% compared with 2.7% on placebo. That's a modelled figure, not a promise of what you'll lose.
The Rybelsus and Wegovy trials used different people, different lengths of time and different designs. Their averages can't be compared directly, and they don't predict how you'll respond.
Can Rybelsus be used for weight loss?
Rybelsus isn't licensed for weight loss. It's licensed for adults with type 2 diabetes.1 In the UK, prescribing a medicine outside its licence is the individual prescriber's clinical responsibility, and there's no approved route for using Rybelsus for weight management.
In PIONEER 1, people with type 2 diabetes on the highest dose lost around 2.3kg more than placebo over 26 weeks.6 OASIS 4 tested a different dose, in people without diabetes, over a different length of time.7 So the two results can't be ranked against each other, and neither predicts how you'd respond.
If you have both type 2 diabetes and obesity, speak to your GP or diabetes team about your options. Do not use Rybelsus for weight loss unless a prescriber has decided it's right for you.
If you want to manage your weight, the licensed UK options are the Wegovy injection and Wegovy semaglutide tablets, which received MHRA approval on 11 June 2026.4
Which semaglutide tablet is right for me?
The two products meet different clinical needs, and one isn't a substitute for the other.
Have type 2 diabetes that isn't well managed on your current medicines? Rybelsus may be an option your GP or diabetes specialist considers. The right choice depends on your existing medicines, blood sugar targets, kidney function and other clinical factors. Trulicity (dulaglutide) is another GLP-1 medicine licensed for type 2 diabetes.
Do not buy semaglutide tablets from unregulated websites. Only use a registered UK pharmacy or prescriber.
Want to manage your weight? Wegovy is the licensed semaglutide option for that in the UK, as an injection or as tablets if you'd rather avoid needles. Wegovy tablets are licensed whether or not you also have type 2 diabetes.2
Neither product should be taken without a valid prescription from a registered UK prescriber. A prescriber will check your medical history, medicines and treatment history, then decide whether they can supply it. Not sure which treatment suits you? Speak to your GP or an online prescribing clinician.
For pricing, see our Wegovy tablet pricing guide.
Weighing up oral GLP-1 options more broadly? Foundayo (orforglipron) is another tablet worth knowing about. Unlike Wegovy tablets and Rybelsus, it contains orforglipron rather than semaglutide, and it's made by Eli Lilly.
The MHRA authorised it on 10 August 2026 for weight management and type 2 diabetes, making the UK the first country in Europe to approve it.8
When to seek medical advice
Speak to your prescribing clinician if you:
- Experience persistent or severe nausea, vomiting, or abdominal pain after starting either medicine
- Have been taking Rybelsus for weight management without a prescription or outside its licensed use and have concerns
- Notice symptoms of low blood sugar such as shakiness, sweating, or confusion, particularly if you also take insulin or a sulfonylurea
- Have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, so your prescriber can take this into account
Stop taking your tablets and get urgent medical help if you have severe, persistent tummy pain, especially if it spreads to your back, with or without being sick. It can be a sign of pancreatitis. Do not restart unless a clinician tells you to. If pancreatitis is confirmed, you must not restart.1,2
Pancreatitis can be serious. Pain that is severe, lasts and spreads to your back needs urgent medical help.
You can report any suspected side effects directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
Frequently asked questions
Is Rybelsus the same as Wegovy tablets?
No. Both contain semaglutide, but they're different medicines with different licences. Rybelsus is licensed in the UK for type 2 diabetes, at doses up to 9mg. Wegovy tablets are licensed for weight management, with a maintenance dose of 25mg. Their dose ranges overlap at 1.5mg, 4mg and 9mg, but the two products are not interchangeable. Do not swap them or take them together unless a prescriber tells you to.
Can I take Rybelsus for weight loss?
Rybelsus isn't licensed for weight loss in the UK. It's approved for adults with type 2 diabetes. Using it for weight management would be off-label. If you have type 2 diabetes and obesity, speak to your GP or diabetes team about your options. If you want to manage your weight with semaglutide, the licensed UK options are the Wegovy injection and Wegovy semaglutide tablets, which the MHRA approved on 11 June 2026.
Why is the Wegovy semaglutide tablet dose so much higher than Rybelsus?
The two medicines are licensed for different uses and have different dose ranges. Only a small share of an oral semaglutide dose reaches your bloodstream, so the tablets need much higher doses than the injection. In people with overweight or obesity, the 25mg Wegovy tablet gave average blood levels similar to the weekly 2.4mg Wegovy injection. Do not take extra Rybelsus tablets to copy a higher dose. Rybelsus is one tablet a day, and taking more is an overdose.
Are Wegovy tablets available in the UK?
Wegovy tablets were approved by the MHRA on 11 June 2026 for weight management in adults who meet the BMI criteria. They're prescription-only. A prescriber will check your medical history, medicines and treatment history, then decide whether they can supply them. Rybelsus is also prescription-only and is licensed for type 2 diabetes only.
Do Rybelsus and Wegovy tablets have the same side effects?
The side effects are broadly similar because both contain semaglutide. The most common are nausea, diarrhoea, vomiting, constipation and tummy discomfort, particularly when you start or the dose goes up. Tell your prescriber if you have had pancreatitis, or if you or a family member has had medullary thyroid cancer or multiple endocrine neoplasia type 2. Stop taking the tablets and get urgent medical help if you have severe, persistent tummy pain, especially if it spreads to your back. Do not restart if pancreatitis is confirmed.
Do both tablets need to be taken on an empty stomach?
Yes. Take either tablet after a fast of at least 8 hours, swallowed whole with a sip of water (up to 120ml). Then wait at least 30 minutes before eating, drinking or taking other oral medicines. This isn't optional. Food and large amounts of water reduce how much semaglutide you absorb, and waiting less than 30 minutes lowers absorption.
References
- Novo Nordisk A/S. Rybelsus 1.5mg, 4mg and 9mg tablets: Summary of Product Characteristics. Electronic Medicines Compendium (eMC); 2026. medicines.org.uk
- Novo Nordisk A/S. Wegovy 25mg tablets: Summary of Product Characteristics. Electronic Medicines Compendium (eMC); 2026. medicines.org.uk
- Medicines and Healthcare products Regulatory Agency. Rybelsus (semaglutide tablets): transition to new formulation and risk of medication error. Drug Safety Update. GOV.UK; 17 December 2025. gov.uk
- Medicines and Healthcare products Regulatory Agency. First GLP-1 tablet for weight loss approved in the UK. GOV.UK; 11 June 2026. gov.uk
- Buckley ST, et al. Transcellular stomach absorption of a derivatised glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
- Aroda VR, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. doi:10.2337/dc19-0749
- Wharton S, et al. Oral semaglutide at a dose of 25mg in adults with overweight or obesity. New England Journal of Medicine. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
- Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK; 2026. gov.uk
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns.